SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association for Continuing Education
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine At Hofstra/Northwell University
Vice President
Advanced Internal Medicine Group, P.C.
East Hills, NY

Nicole Swiner, MD
Adjunct Associate Professor of Family Medicine
UNC Chapel Hill
Partner of Durham Family Medicine
Durham, NC

: Insulin Therapy and Glycemic Variability: Strategies for Achieving Diabetes Goals While Minimizing Hypoglycemia
Activity/Course #:
: NCME385
: Free
Release/Start Date:
: Jul 30 2019
Expiration Date:
: Jul 29 2020
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Due to progressive β-cell dysfunction in type 2 diabetes (T2DM), traditional oral drugs such as metformin and sulfonylureas are often inadequate for achieving/maintaining long-term glycemic control, and ultimately most patients need insulin-providing therapy for managing their disease. However, a variety of factors lead to underuse of insulin, resulting in unnecessary suboptimal glycemic control. New preparations of concentrated and long-acting insulins are available and may be appropriate for individualized therapy. This activity will examine the risk and impact of hypoglycemia, strategies to reduce the risk of glycemic variability, strategies for use of SMBG and CGM devices, and use of available insulin preparations for improved patient outcomes.

This webcast was recorded live at the Emerging Challenges in Primary Care 2019 Live Virtual Symposium and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Recognize the risk for, and impact of, hypoglycemia in patients with diabetes
  2. Integrate strategies to reduce the risk of glycemic variability into the care of patients with diabetes
  3. Recognize how to use SMBG or newer CGM devices to reduce the risk of dysglycemia/hypoglycemia
  4. Differentiate between available insulin preparations and their effects on glycemic variability and hypoglycemic risk
How to obtain the CME Certificate
  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. All planners are also required to disclose all relevant financial relationships. Disclosure information is provided below.

Dr. Morales is a speaker and consultant at Novo Nordisk, Abbott, Lilly, Boehringer Ingelheim

Dr. Swiner has no relationships to disclose

Contributing Faculty
Mark Stolar, MD has no relationships to disclose.

Jeff Unger, MD, FAAFP, FACE serves as a speaker and consultant for Novo Nordisk, and Abbott Diabetes

Activity Planning Committee
Gregg Sherman, MD, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Novo Nordisk, Inc.